Adalimumab
Modify Date: 2025-08-21 10:30:21
Adalimumab structure
|
Common Name | Adalimumab | ||
|---|---|---|---|---|
| CAS Number | 331731-18-1 | Molecular Weight | 434.46288 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C6428H9912N1694O1987S46 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AdalimumabAdalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). |
| Name | Unii-fys6T7F842 |
|---|
| Description | Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). |
|---|---|
| Related Catalog | |
| In Vitro | Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF-α) than used in this study[2]. |
| In Vivo | The elimination half-life (t1/2) of Adalimumab (anti-TNF-α) is long (~20 days)[1]. The enriched fluorescent-labelled adalimumab (anti-TNF-α) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr-/- mice[2]. |
| References |
| Molecular Formula | C6428H9912N1694O1987S46 |
|---|---|
| Molecular Weight | 434.46288 |